Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors
- Registration Number
- NCT00687934
- Lead Sponsor
- Synta Pharmaceuticals Corp.
- Brief Summary
An open-label dose escalation study of patients with solid tumors treated with STA-9090 (ganetespib)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 53
Inclusion Criteria
- Patients must be documented to be refractory or not candidates for current approved therapies.
- Must have an ECOG status 0-2.
- Peripheral neuropathy < or = 2.
- Must have acceptable organ and marrow function per protocol parameters.
- No clinically significant ventricular arrythmias or ischemia.
Exclusion Criteria
- Must not be pregnant or breastfeeding.
- Chemotherapy or radiation within 3 weeks.
- Previous radiation to >25% of total bone marrow.
- Previous high dose chemotherapy with autologous or allogeneic hematopoietic stem cell transplantation.
- Primary brain tumors or active brain metastases.
- Use of any investigational agents within 4 weeks.
- Treatment with chronic immunosuppressants.
- Uncontrolled, intercurrent illness.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Ganetespib STA-9090 Ganetespib once weekly infusion, dose escalation study, with treatment until progression
- Primary Outcome Measures
Name Time Method The safety and tolerability of STA-9090 (ganetespib) in cancer patients via assessment of dose limiting toxicities Cycle 1
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Premiere Oncology
🇺🇸Santa Monica, California, United States
US Oncology Dayton Oncology and Hematology, P.A
🇺🇸Kettering, Ohio, United States